RxDoctor Payments DataLook up a doctor →

James Hunt, DO

Rheumatology · Thomasville, GANPI 1083811442

Payments from drug & device makers

$159,758in general payments, 2019–2025

Across 913 payments — averaging $174.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$150K
  • Johnson & Johnson$2K
  • AbbVie$2K
  • UCB, Inc.$1K
  • AstraZeneca$627
  • Mallinckrodt Hospital Products Inc.$503
  • plus $3K from 34 others

What the payments were for

  • Speaking & faculty fees$125,93779%
  • Travel & lodging$17,33111%
  • Food & beverage$16,10610%
  • Education$3840%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$159,758 in reported general payments places this provider in the 90th percentile of 177 rheumatology providers in Georgia.

See all rheumatology providers in Georgia

Medicare billing

Part B allowed, 2024
$115,465
Medicare patients
393
Services billed
2,739

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KrystexxaPegloticase71$2,489,760
RinvoqUpadacitinib268$1,775,157
Enbrel SureclickEtanercept173$1,281,335
Humira(Cf) PenAdalimumab139$1,006,219
Skyrizi PenRisankizumab-Rzaa24$496,820
Orencia ClickjectAbatacept78$441,542
Xeljanz XrTofacitinib Citrate61$380,155
TremfyaGuselkumab26$356,915
Cosentyx Unoready PenSecukinumab32$235,934
KevzaraSarilumab45$191,305
OrenciaAbatacept27$164,803
Actemra ActpenTocilizumab30$143,700
Cosentyx Sensoready (2 Pens)Secukinumab17$125,232
Enbrel MiniEtanercept16$123,583
HumiraAdalimumab12$80,769

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenKrystexxa$149,976$2,489,76071 claims
AbbVieRinvoq, Humira$2,021$1,855,926280 claims
Johnson & JohnsonTremfya$2,023$356,91526 claims
SanofiKevzara$267$191,30545 claims
E.r. Squibb & Sons, L.L.C.Orencia$88$164,80327 claims
UCB, Inc.Cimzia (2 Pack)$1,203$68,98212 claims
Radius Health, Inc.Tymlos$66$37,25312 claims
Scilex Pharmaceuticals Inc.Colchicine$36$7,43588 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 177 rheumatology providers in Georgia.

Other rheumatology in Thomasville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →